Cremaffin

Quick links to important sections

Cremaffin

Method of action: Laxative

Treatment option: Hemorrhoids, Constipation, Proctitis

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cremaffin

Property Description
Active Ingredients Magnesium Hydroxide, Liquid Paraffin
Form Oral Emulsion / Suspension
Pharmacological Class Antacid and Laxative
Common Use Relief of Acidity and Constipation
Origin Semi-synthetic (Combination)

Cremaffin is a recognized brand of oral liquid preparation that functions as a combination Gastrointestinal Agent, exhibiting both antacid and laxative properties. It is typically formulated as an oral emulsion or suspension designed for non-systemic action within the digestive tract. The preparation is considered semi-synthetic, featuring an inorganic compound and a refined hydrocarbon derivative.


What Kind of Medicine is Cremaffin? (Identity and Class)

The preparation's classification is defined by its ability to provide two distinct therapeutic effects, making it a dual-acting compound. Magnesium Hydroxide is recognized as having roles as both an antacid and a saline laxative. The magnesium component works by increasing water in the intestines and neutralizing stomach acid, a mechanism that provides relief of heartburn symptoms. This dual functionality positions Cremaffin as a pharmaceutical preparation for common, co-occurring digestive symptoms, differentiating it from single-class laxatives by its immediate anti-acidity action. It is generally available over the counter (OTC) in its primary markets.


Composition: Magnesium Hydroxide and Liquid Paraffin

The efficacy of Cremaffin is based on the combination of two active ingredients: the inorganic compound Magnesium Hydroxide and Liquid Paraffin (also known as Paraffin Liquid). As an inorganic compound, Magnesium Hydroxide neutralizes existing quantities of stomach acid. Liquid Paraffin is a highly refined mineral oil, classified as a lubricant laxative. The role of Liquid Paraffin is to lubricate the contents of the intestine, facilitating easier movement. These two active substances are held together within an aqueous vehicle, forming a stable emulsion, often featuring specific flavoring to enhance palatability for patients.


What is the General Purpose of Cremaffin? (High-Level Benefit)

The primary purpose of Cremaffin is to alleviate discomfort associated with excess stomach acid while simultaneously promoting the comfortable passage of stool. This makes it a standard choice for a scenario where a patient experiences both temporary heartburn and concurrent difficulty with bowel movement. The antacid function targets the upper GI tract, reducing acidity, while the combined osmotic effect of Magnesium Hydroxide and the lubricating action of Liquid Paraffin address the physical challenge of hardened fecal matter.

Regulatory References

  1. NIH DailyMed: Magnesium Hydroxide
  2. MedlinePlus: Magnesium Hydroxide

What side effects are possible with Cremaffin?

Possible Side Effects and Safety Information

The safety profile for this combination preparation of Magnesium Hydroxide and Liquid Paraffin is primarily structured around effects related to its action in the gastrointestinal system, as documented in official regulatory labeling. These effects are classified within the Gastrointestinal Disorders System-Organ Class.

Officially Documented Adverse Reactions

The most Common adverse reactions reported are related to the laxative component, often being dose-dependent. These effects include diarrhoea, abdominal discomfort, and cramping or pain. Other potential effects listed in regulatory documents include bloating and flatulence.

Serious Adverse Reactions and Safety Constraints

The most significant systemic safety concern is the risk of Hypermagnesemia (high magnesium levels in the blood). This risk is conditional and is explicitly noted in labeling for individuals with pre-existing kidney disease or renal impairment due to reduced clearance of magnesium

. Symptoms related to high magnesium levels can involve Nervous System Disorders, such as confusion or drowsiness.

A serious, though rare, hazard is the risk of Lipoid Pneumonia, particularly in susceptible populations like children. This occurs due to the aspiration of the Liquid Paraffin component. Additionally, the label documents the potential for allergic or hypersensitivity reactions.

Use is subject to specific constraints and is advised against in the presence of acute abdominal symptoms, including severe abdominal pain, vomiting, rectal bleeding, or suspected intestinal obstruction. Furthermore, regulatory information advises against prolonged use—typically more than seven days—to avoid the officially documented risk of developing a dependency on the laxative effect.

Overdose and Emergency Response

Overdose and when to seek help

The official overdose profile for this combination product is primarily focused on the systemic risks associated with the Magnesium Hydroxide component. An overdosage, or impaired elimination, can lead to elevated magnesium concentrations in the body, a condition known as hypermagnesemia, as documented in regulatory information.

Documented Overdose Manifestations

Initial clinical signs of hypermagnesemia may include flushing, drowsiness, nausea, vomiting, and hypotension (low blood pressure). Of critical note is the progressive decrease in deep tendon reflexes, which serves as a recognized clinical indicator of increasing magnesium intoxication severity.

Severe Outcomes and Emergency Action

High systemic magnesium levels are formally documented to lead to severe and potentially life-threatening complications. These include profound central nervous system depression, respiratory paralysis, circulatory collapse, and cardiac arrest. The risk of these severe outcomes is increased in patients with renal impairment or kidney disease, as magnesium is eliminated solely by the kidneys.

Regulatory documents mandate that individuals who suspect an overdose, or who experience severe symptoms such as shortness of breath, profound muscle weakness, or loss of consciousness, must seek immediate emergency medical attention or contact a Poison Help line right away.

In the documented medical management of severe magnesium intoxication, an injectable calcium salt is officially described as the specific agent available to antagonize the effects of magnesium, alongside necessary supportive care and continuous monitoring of serum magnesium levels.

Therapeutic Uses of Cremaffin

Cremaffin is commonly used in therapeutic domains where symptomatic assistance for both the lower and upper gastrointestinal tracts is appropriate. The key ingredient has recognized laxative and antacid properties. The preparation is utilized in contexts involving symptoms that create noticeable physiological strain or interfere with daily comfort.


Easing Difficult Bowel Movements and Hyperacidity

This medication is applied in situations involving certain distressing symptoms of occasional constipation, such as hard stools and infrequent defecation, and for symptomatic support for upper gastrointestinal hyperacidity, including heartburn and general acid indigestion. The core benefit plays a role in managing a more gentle passage of stool and assisting with easing acid-related discomfort. The preparation is relevant for managing symptoms in situations where reduced straining during defecation is a relevant consideration, such as managing painful bowel movements associated with piles (haemorrhoids) or anal fissures. This offers symptomatic relief that may assist with maintaining comfort and coping more steadily with these difficult episodes.


Quick Fact: Symptomatic Support for Digestive Discomfort Therapeutic Areas Key Symptoms Managed Patient Benefit
Gastrointestinal Motility Hard, dry stools, infrequent defecation Promotes gentler, easier passage
Gastric Acidity Heartburn, acid indigestion Relevant for acute symptomatic relief

Regulatory References

  1. NIH MedlinePlus overview on Magnesium Hydroxide

Eligibility and Restrictions for Use

Population Eligibility and Contraindications

The eligibility profile for the combination medicine Cremaffin (Magnesium Hydroxide and Liquid Paraffin) is strictly defined by regulatory authorities based on age, organ function, and pre-existing conditions.

Absolute Contraindications

Use is prohibited for patients with a known hypersensitivity to the active ingredients or excipients. The medicine is contraindicated in patients with severe renal failure due to the risk of magnesium toxicity and in cases of suspected or confirmed intestinal obstruction, undiagnosed acute abdominal pain, or rectal bleeding.

Age-Based Restrictions

Use is contraindicated in children under 2 years of age. Furthermore, due to the specific risk of aspiration from the Liquid Paraffin component, the medicine is generally not recommended for children under 6 years or for bedridden elderly patients and those with swallowing difficulties.

Conditional Use

Caution is required for patients with impaired kidney function or impaired liver function. Use during pregnancy is generally not recommended, and use during lactation should be approached with caution and medical consultation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the official interaction patterns for Cremaffin’s active components, Magnesium Hydroxide and Liquid Paraffin, as described in governmental regulatory documents.

Exposure and Absorption Alterations

The Magnesium Hydroxide component may reduce the plasma levels and therapeutic effect of certain co-administered medicines, including specific antivirals, iron salts, and tetracycline antibacterials. This interference with absorption is due to the alteration of gastric pH. The Liquid Paraffin component carries a documented risk of reduced serum concentration for fat-soluble vitamin derivatives (such as calcifediol or calcitriol) by decreasing their absorption.

Regulatory Restrictions and Risks

Official regulatory documents mandate the separation of administration between this product and medicines sensitive to gastric pH alteration to mitigate interaction risk. Co-administration with other magnesium-containing preparations is restricted due to an additive pharmacodynamic risk that increases the risk of hypermagnesemia and potential magnesium toxicity. This population-specific risk is significantly elevated in patients with renal impairment or renal disease, and is also noted for the elderly population due to the risk of magnesium accumulation.

Mechanism of Action

The physiological effects of this combination medicine are achieved through three independent, localized mechanistic domains targeting distinct systems within the gastrointestinal tract, ensuring a comprehensive physiological adjustment in the gastrointestinal tract.

Chemical Buffering of Gastric Acidity

This domain involves the rapid, direct interaction of Magnesium Hydroxide (Mg(OH)2) with the primary target, hydrochloric acid (HCl), inside the stomach lumen. The mechanism is a simple neutralization reaction, where the base consumes the existing acid load, quickly elevating the gastric pH. This chemical modulation reduces the corrosive activity on the mucosal surface, leading to a reduction in local chemical irritation of the mucosal surface.

Osmotic Modulation of Intestinal Fluid Dynamics

In the lower gastrointestinal tract, the poorly absorbed Magnesium ions create an osmotic pressure gradient. This physical force draws and retains water from the surrounding tissues into the colon's lumen, causing a change in intestinal fluid dynamics. The resulting cascade leads to a significant softening and bulking of the fecal mass, which physically stimulates the colon's smooth muscle tissue and subsequently results in the mechanical stimulation of colonic smooth muscle and subsequent movement.

Physical Lubrication and Reduced Frictional Resistance

The third domain is driven by Liquid Paraffin, an inert agent that acts as a physical barrier. It coats the surface of the fecal mass and the intestinal lining, thereby reducing the frictional resistance during transit. This lubrication mechanism complements the osmotic action by externally facilitating the passage of the softened and bulked contents, while also retarding water reabsorption.

Dosage and Administration Information

How Cremaffin is Used: Administration Guidelines

Cremaffin, an oral liquid preparation containing Magnesium Hydroxide and Liquid Paraffin, is administered via the oral route as an emulsion or suspension. Proper usage is determined by the specific condition being addressed, either occasional constipation or hyperacidity.

Preparation and Standard Adult Dosing

Before measuring a dose, the liquid product must be shaken well to ensure uniform distribution of the active components. Dosing requires the use of an accurate measuring device (cup or spoon) and is generally standardized for adults (ages 12 and over):

  • For Constipation Relief: The standard dose ranges from 15 mL to 30 mL, typically taken once daily at bedtime. The maximum recommended daily intake should not exceed 60 mL over 24 hours.
  • For Acidity Relief: The dose is typically lower, between 5 mL and 15 mL, and may be repeated up to four times per 24-hour period as needed.

Administration Requirements and Duration

When used as a laxative, the dose must be followed by a full glass of liquid to support the osmotic action and aid in bowel movement. Adherence to this fluid requirement is a core administration principle. The medicine is intended for short-term use only. For constipation, usage should not extend beyond seven consecutive days unless specifically directed by a healthcare professional, as prolonged, unsupervised administration is generally not advised.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cremaffin

Evidence Supporting the Laxative Action for Constipation Relief

The research landscape for the active ingredients used in Cremaffin was evaluated using Randomized Controlled Trials (RCTs) and Systematic Reviews focused on Magnesium Hydroxide and Liquid Paraffin. Research examined studies evaluating patient-reported experiences related to bowel movements and outcomes related to physical discomfort. Studies monitored adults with functional constipation and, in component research, children. Non-comparative studies described data show patterns related to functional scores in patients with constipation associated with anal fissures or haemorrhoids. However, comparative evidence is lacking directly for this specific two-ingredient formulation, and the evidence quality varies across studies, with some aggregate analyses suggesting certainty remains low.

Evidence Supporting the Antacid Action for Hyperacidity

Evidence for the antacid component was studied for its use in managing acid-related discomfort and is described in Regulatory Monographs and Pharmacological Studies related to Magnesium Hydroxide. This component was studied for its ability to neutralize stomach acid in trials assessing short-term or episodic symptom patterns like heartburn. Researchers examined outcomes related to physical discomfort and changes in gastric acidity. Studies monitored the speed at which symptomatic relief was reported. Comparative evidence is lacking for this dual-ingredient suspension against other single-ingredient antacid products, and evidence remains limited beyond the established regulatory classification of the Magnesium Hydroxide component.

Research on Study Duration and Long-Term Use and Uncertainty

The majority of intervention research for the active components has focused on relatively short timeframes, with follow-up durations limited to periods such as four to eight weeks. Long-term effects are not fully established for the combined product, and there is limited information for long-term outcomes or durability of effect. Additionally, comparative evidence is lacking for the specific two-ingredient formulation in high-quality RCTs, and sample sizes were modest in some published research. The evidence quality varies across studies, and research does not determine whether an individual will respond similarly to the group patterns described in the findings.

Key Studies & References NIH MedlinePlus Drug Information: Magnesium Hydroxide (Antacid and Laxative properties)

Frequently Asked Questions (FAQ)

Common questions about Cremaffin (FAQ)

Q: Is Cremaffin a prescription medicine, or can I buy it over the counter?

A: According to official product information and regulatory monographs, this preparation is generally available over the counter (OTC) in its primary markets. It is not typically classified as a medicine that requires a prescription for purchase.


Q: What are the official warnings listed for Cremaffin?

A: Official warnings focus on a few key areas, including the risk of hypermagnesemia (high magnesium levels in the blood), especially for individuals with kidney disease. There is also a specific, rare risk of aspiration leading to lipoid pneumonia, particularly noted for children and bedridden elderly. Due to the risk of dependency, prolonged use beyond seven consecutive days is advised against.


Q: Are there any known issues with taking Cremaffin while pregnant or breastfeeding?

A: Regulatory safety advice generally indicates that use during pregnancy is not recommended. For use during breastfeeding (lactation), official product information states that it should be approached with caution and is subject to the guidance of a healthcare professional.


Q: Can Cremaffin affect how other medicines I take are absorbed?

A: Yes, official documents indicate potential interactions. The Magnesium Hydroxide component can change the stomach's pH, potentially reducing the absorption and therapeutic effect of certain medicines like antivirals and iron salts. The Liquid Paraffin component also carries a risk of reducing the absorption and serum concentration of fat-soluble vitamins.


Q: Can a person with diabetes use Cremaffin, and is there sugar in it?

A: The suitability for people with diabetes often depends on the specific product formulation. Some marketed products, such as Cremaffin Plus, are explicitly labeled as 'Sugar Free,' which is a formulation noted for diabetic consumers. Confirmation of suitability requires review of the specific product label.


Q: Are there any official reports of serious allergic reactions to Cremaffin?

A: The product label documents the potential for allergic or hypersensitivity reactions, although they are rare. Signs of allergic reaction described as serious include hives, difficulty breathing, or swelling of the face, lips, tongue, or throat.


Q: If I have kidney problems, is Cremaffin use still described as appropriate?

A: Official information provides clear distinctions based on the severity of the condition. Use is strictly prohibited (contraindicated) for patients with severe renal failure. Caution is required for patients with impaired kidney function due to the risk of magnesium accumulation and toxicity.


Q: How is the dose for Cremaffin generally described for adults?

A: The dosage described for adults (12 years and over) depends on the condition being treated. For constipation relief, a larger dose range is typically described once daily. For acidity relief, a smaller dose is generally described, which may be repeated up to four times daily as needed.


Q: What are the signs that Cremaffin is working as intended?

A: As a laxative, the product's function is generally associated with producing a bowel movement within a timeframe of 30 minutes to 12 hours after administration, alongside the relief of constipation or stomach acidity symptoms.


Q: Does Cremaffin cause gas or bloating as a side effect?

A: Yes, regulatory documents list potential adverse reactions that are classified within the Gastrointestinal Disorders system. These effects can include bloating and flatulence, in addition to the more common effects like abdominal discomfort and diarrhoea.


Q: How quickly should I expect Cremaffin to start working?

A: Based on product information, the preparation generally produces a bowel movement within 30 minutes to 12 hours after administration when used as a laxative. The timeframe of 6 to 8 hours is often cited as a period during which effects may be observed.


Q: Can Cremaffin be used for long-term or regular constipation issues?

A: No. Official documents state that the medicine is intended for short-term use only. Usage should not extend beyond seven consecutive days unless specifically directed by a healthcare professional, reflecting the risk of developing a dependency on the laxative effect.


Q: Does Cremaffin cause any kind of dependence or withdrawal effects?

A: Prolonged use or overuse carries an officially documented risk of developing a dependency on the laxative effect, which can result in the worsening of constipation over time. This risk is a key reason for the short-term use constraint.


Q: What is the recommended duration of time to use Cremaffin before stopping?

A: For the relief of constipation, official guidelines state that usage should not extend beyond seven consecutive days. The drug label emphasizes stopping the use if symptoms improve or before this period is reached, unless a healthcare professional has provided different guidance.


Q: Are there certain foods or drinks that should be avoided while using Cremaffin?

A: While regulatory sources do not prohibit specific foods, the administration guidelines emphasize a core fluid requirement. The laxative dose must be followed by a full glass of liquid to support its osmotic action. General health advice recommends maintaining a balanced diet and staying hydrated.


Q: Is it normal to feel a change in taste after taking Cremaffin?

A: Yes, a decreased sense of taste has been listed as a potential common side effect related to the Magnesium Hydroxide component of the medicine. This is a documented, though not universal, experience.


Q: Does using Cremaffin require any changes to diet or water intake?

A: Yes, adherence to a fluid requirement is a core administration principle for the laxative effect. The dose must be followed by a full glass of liquid. Staying hydrated throughout the day is generally recommended by official sources to support bowel function.


Q: What should I do if I miss a scheduled time to take Cremaffin?

A: Regulatory sources generally advise taking a missed dose as soon as it is remembered. However, if it is almost time for the next scheduled dose, the product label describes skipping the missed dose and continuing with the regular schedule, noting that doses should not be doubled.


Q: Does taking Cremaffin at night affect sleep?

A: For constipation relief, the medicine is typically recommended for use at bedtime, timed to align with its expected onset of effect in the morning. While the product is not primarily noted for affecting sleep, documented side effects include potential drowsiness (a sign of high magnesium level) or abdominal cramping.


Q: Is it possible to become dehydrated from using Cremaffin?

A: Because diarrhoea is a common side effect of the laxative component, it can lead to fluid loss. Official safety advice highlights the importance of fluid intake while using the product to help mitigate the risk of dehydration associated with diarrhoea.


Q: Does Cremaffin have a specific recommended time of day for taking it?

A: Yes. For the relief of constipation, the product is typically recommended to be taken once daily at bedtime. This timing is generally advised to ensure the laxative effect occurs the following morning.


Q: Can Cremaffin be mixed with water or other liquids?

A: Yes, some regulatory and product information suggests that the suspension can be taken directly or mixed with a small amount of water or juice. This method is often used to make the emulsion easier to swallow.


Q: Does Cremaffin contain any artificial sweeteners or colors?

A: Some marketed products are explicitly labeled as 'Sugar Free,' which is typically achieved through the use of non-sugar sweeteners. The presence of specific colors may vary by brand variant, and this information is generally found on the specific product label.


Q: Can Cremaffin cause nutrient deficiencies if used for an extended period?

A: Yes. The Liquid Paraffin component carries a documented risk of reduced serum concentration and absorption of fat-soluble vitamins, such as vitamins A, D, E, and K. This potential interference is a primary reason prolonged use is advised against in official warnings.


Q: What if I take Cremaffin but my symptoms do not improve?

A: Regulatory warnings describe circumstances where discontinuing use and seeking guidance from a healthcare professional is appropriate, such as if symptoms last for more than two weeks, worsen, or do not start to get better after initial use. Continued use should not exceed the recommended duration.


Q: Are there known drug interactions with antacids and Cremaffin?

A: Yes. Co-administration with other magnesium-containing preparations, including many antacids, is restricted. This is due to an additive risk that increases the potential for hypermagnesemia (high magnesium levels in the blood) and associated magnesium toxicity.

How should Cremaffin be stored and disposed of?

Storage and Disposal Requirements for Cremaffin

The official storage conditions for Cremaffin (Magnesium Hydroxide/Liquid Paraffin oral suspension) are designed to maintain product integrity and safety.

Storage Conditions

Cremaffin must be stored at room temperature, generally below 30 C and should be protected from light and moisture. It is required to keep the medicine in its original container and ensure the cap is tightly closed when not in use. Do not freeze the suspension, as this may compromise the product's formulation. A mandatory regulatory requirement is to keep the medicine out of the sight and reach of children and pets at all times.

Disposal Instructions

Dispose of any unused or expired Cremaffin product. The unused medication must be discarded after its expiration date. Consult a healthcare professional or pharmacist regarding local procedures for discarding unused medicine to ensure proper handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cremaffin found in:

A-Z Index: